Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Senicapoc

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 289656-45-7, 2,2-bis(4-fluorophenyl)-2-phenylacetamide, Ica-17043, Senicapoc (usan), Senicapoc [usan], Ts6g201a6q
    Molecular Formula
    C20H15F2NO
    Molecular Weight
    323.3  g/mol
    InChI Key
    SCTZUZTYRMOMKT-UHFFFAOYSA-N
    FDA UNII
    TS6G201A6Q
    Senicapoc is an orally bioavailable inhibitor of the calcium-activated potassium channel KCa3.1 (Gardos channel; KCNN4; IK-1; SK4), with potential anti-inflammatory and immunomodulatory activities. Upon oral administration, senicapoc targets, binds to and inhibits KCa3.1. KCa3.1 regulates membrane potential and calcium signaling in a variety of cells including erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. The inhibition of KCa3.1 may prevent erythrocyte dehydration in sickle cell disease, reduce fluid secretion, fluid retention and inflammation in the lungs in acute respiratory distress syndrome (ARDS), and reduce inflammation and immune responses in various other diseases such as neuroinflammation in Alzheimer's disease. Senicapoc exhibits good brain penetration.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2,2-bis(4-fluorophenyl)-2-phenylacetamide
    2.1.2 InChI
    InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
    2.1.3 InChI Key
    SCTZUZTYRMOMKT-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
    2.2 Other Identifiers
    2.2.1 UNII
    TS6G201A6Q
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bis(4-fluorophenyl)phenylacetamide

    2. Ica 17043

    3. Ica-17043

    4. Ica17043

    2.3.2 Depositor-Supplied Synonyms

    1. 289656-45-7

    2. 2,2-bis(4-fluorophenyl)-2-phenylacetamide

    3. Ica-17043

    4. Senicapoc (usan)

    5. Senicapoc [usan]

    6. Ts6g201a6q

    7. Pf-05416266

    8. Benzeneacetamide, 4-fluoro-alpha-(4-fluorophenyl)-alpha-phenyl-

    9. Bis(4-fluorophenyl)phenylacetamide

    10. Senicapoc [usan:inn]

    11. Ica 17043

    12. Unii-ts6g201a6q

    13. 2,2-bis(4-fluorophenyl)-2-phenyl-acetamide

    14. 4-fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide

    15. Senicapoc [inn]

    16. Senicapoc [mart.]

    17. Senicapoc [who-dd]

    18. Chembl405821

    19. Gtpl2331

    20. Schembl1443805

    21. Amy2744

    22. Dtxsid60276906

    23. Hms3741e13

    24. Act06676

    25. Bcp14507

    26. Zinc3816408

    27. Bbl102413

    28. Bdbm50371391

    29. Mfcd09027349

    30. Stl556215

    31. Akos007930800

    32. Cs-0294

    33. Db06280

    34. 4-methyl-1h-pyrrole-2-carboxylic?acid

    35. Hy-50694

    36. Ms-20434

    37. Db-003217

    38. Ft-0660387

    39. 2,2-bis(4-fluorophenyl)-2-phenyl-ethanamide

    40. C74487

    41. D06640

    42. 656f457

    43. A822267

    44. A904983

    45. Au-004/43508060

    46. Q7450628

    47. 4-fluoro-a-(4-fluorophenyl)-a-phenyl-benzeneacetamide

    2.4 Create Date
    2005-08-09
    3 Chemical and Physical Properties
    Molecular Weight 323.3 g/mol
    Molecular Formula C20H15F2NO
    XLogP34.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count3
    Rotatable Bond Count4
    Exact Mass323.11217043 g/mol
    Monoisotopic Mass323.11217043 g/mol
    Topological Polar Surface Area43.1 Ų
    Heavy Atom Count24
    Formal Charge0
    Complexity397
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in anemia (sickle cell) and asthma.